Related Experiment Video
Updated: Sep 8, 2025
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.7K
β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2
Maria S Svane1,2,3, Morten Hindsø1, Christoffer Martinussen1
1Department of Endocrinology, Hvidovre Hospital, Copenhagen University, Hvidovre, Denmark.
Diabetes
|July 3, 2025
Summary
Roux-en-Y gastric bypass enhances type 2 diabetes management, but doesn't improve beta-cell sensitivity to incretins like GLP-1 and GIP. Other factors drive improved beta-cell function post-surgery.
Area of Science:
- Metabolic Surgery
- Endocrinology
- Diabetes Research
Background:
- Roux-en-Y gastric bypass (RYGB) significantly improves glycemic control in type 2 diabetes.
- The specific effects of RYGB on beta-cell sensitivity to incretins, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), remain incompletely understood.
Purpose of the Study:
- To investigate the impact of RYGB on beta-cell responsiveness to GLP-1 and GIP in patients with type 2 diabetes.
- To determine whether enhanced beta-cell sensitivity to incretins contributes to the glycemic improvements observed after RYGB.
Main Methods:
- Comparative analysis of insulin secretion in response to glucose, GLP-1, and GIP before and after RYGB surgery.
- Utilized clamped hyperglycemia to assess incretin potentiation of insulin release.
Main Results:
- Both GLP-1 and GIP potentiated insulin secretion pre- and post-RYGB during clamped hyperglycemia.
- Postoperatively, the relative potentiating effects of GIP (first-phase) and GLP-1 (first- and second-phase) on insulin secretion, when normalized to glucose response, were reduced.
- Improved beta-cell function post-RYGB is not attributed to enhanced sensitivity to incretins.
Conclusions:
- The beneficial effects of RYGB on beta-cell function in type 2 diabetes are not mediated by increased sensitivity to GLP-1 or GIP.
- Improvements in beta-cell function likely stem from other mechanisms, including enhanced sensitivity to altered glucose levels and increased postprandial GLP-1 secretion.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
415
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
415
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.4K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.4K
01:22Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
01:16Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
01:36Carbohydrate Metabolism
11.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.7K